<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SULFASALAZINE</span><br/>(sul-fa-sal'a-zeen)<br/><span class="topboxtradename">Azulfidine, </span><span class="topboxtradename">PMS Sulfasalazine <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">PMS Sulfasalazine E.C. <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Salazopyrin <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">SAS Enteric-500 <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">S.A.S.-500 <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">mucous membrane agent</span>; <span class="classification">antiinflammatory</span>; <span class="classification">sulfonamide</span><br/><b>Prototype: </b>Mesalamine<br/><b>Pregnancy Category: </b>B  (D if near term)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablets; 500 mg sustained release tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Locally acting sulfonamide. Believed to be converted by intestinal microflora to sulfapyridine (provides antibacterial action)
         and 5-aminosalicylic acid (5-ASA) or mesalamine, which may exert an antiinflammatory effect. Other proposed mechanisms of
         action include inhibition of prostaglandins known to cause diarrhea and affect mucosal transport, and interference with absorption
         of fluids and electrolytes from colon.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces <i>Clostridium</i> and <i>Escherichia coli</i> in the stools. Antiinflammatory and immunomodulatory properties are effective in controlling the S&amp;S of ulcerative colitis
         and rheumatoid arthritis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Ulcerative colitis and relatively mild regional enteritis; rheumatoid arthritis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Granulomatous colitis, Crohn's disease, scleroderma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sensitivity to sulfasalazine, other sulfonamides and salicylates; agranulocytosis; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Severe allergy, or bronchial asthma; blood dyscrasias; hepatic or renal impairment; older adults; lactation; children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ulcerative Colitis, Rheumatoid Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12 g/d in 4 divided doses, may increase up to 8 g/d if needed<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 4050 mg/kg/d in 4 divided doses (max: 75 mg/kg/d)<br/><br/><span class="indicationtitle">Juvenile Rheumatoid Arthritis</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 10 mg/kg/d, increase weekly by 10 mg/kg/d [usual dose: 1525 mg/kg q12h (max: 2 g/d)]<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give after eating to provide longer intestine transit time.</li>
<li>Do not crush or chew sustained release tablets; must be swallowed whole.</li>
<li>Use evenly divided doses over each 24-h period; do not exceed 8-h intervals between doses.</li>
<li>Consult physician if GI intolerance occurs after first few doses. Symptoms are probably due to irritation of stomach mucosa
            and may be relieved by spacing total daily dose more evenly over 24 h or by administration of enteric-coated tablets.
         </li>
<li>Store at 15°30° C (59°86° F) in tight, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Nausea, vomiting, bloody diarrhea; anorexia,</span> arthralgia, rash, anemia, oligospermia (reversible), blood dyscrasias, liver injury, infectious mononucleosislike reaction,
      <span class="speceff-common">allergic reactions.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Iron,</b>
<span class="classification">antibiotics</span> may alter absorption of sulfasalazine. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 1015% absorbed from GI tract unchanged; remaining drug is hydrolyzed in colon to sulfapyridine (most of which is
      absorbed) and 5-aminosalicylic acid (30% of which is absorbed). <span class="typehead">Peak:</span> 1.56 h sulfasalazine; 624 h sulfapyridine. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in intestines and liver. <span class="typehead">Elimination:</span> All metabolites are excreted in urine. <span class="typehead">Half-Life:</span> 510 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for GI distress. GI symptoms that develop after a few days of therapy may indicate need for dosage adjustment. If
            symptoms persist, physician may withhold drug for 57 d and restart it at a lower dosage level.
         </li>
<li>Be aware that adverse reactions generally occur within a few days to 12 wk after start of therapy; most likely to occur in
            patients receiving high doses (4 g or more).
         </li>
<li>Lab tests: Measure RBC folate in patients on high doses (more than 2 g/d); a daily supplement may be prescribed.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Examine stools and report to physician if enteric-coated tablets have passed intact in feces. Some patients lack enzymes capable
            of dissolving coating; conventional tablet will be ordered.
         </li>
<li>Be aware that drug may color alkaline urine and skin orange-yellow.</li>
<li>Remain under close medical supervision. Relapses occur in about 40% of patients after initial satisfactory response. Response
            to therapy and duration of treatment are governed by endoscopic examinations.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>